Elekta AB stock (SE0000163628): recent earnings update keeps focus on radiotherapy demand

Elekta AB has reported its latest quarterly results and updated investors on trends in cancer radiotherapy equipment and software. Here is what the numbers and recent news mean for the Stockholm?listed medtech player and for US-focused investors.

Elekta AB recently presented financial results for its fiscal third quarter 2024/25 and commented on demand trends in radiation oncology solutions, offering fresh insight into the company’s order momentum, profitability, and outlook for the global cancer care market, according to a report published on 02/27/2025 by the company’s investor relations team and covered by regional business media Elekta investor relations as of 02/27/2025.

As of: 05/15/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elekta
• Sector/industry: Medical technology, radiation oncology
• Headquarters/country: Stockholm, Sweden
• Core markets: Radiotherapy systems and oncology software worldwide
• Key revenue drivers: Linear accelerators, brachytherapy, treatment planning and oncology IT
• Home exchange/listing venue: Nasdaq Stockholm (ticker: EKTA B)
• Trading currency: Swedish krona (SEK)

Elekta AB: core business model

Elekta AB focuses on the development and sale of radiation therapy systems, software, and related services that are used in the treatment of cancer and brain disorders. The company’s product portfolio spans linear accelerators for external beam radiotherapy, brachytherapy solutions for internal radiation, stereotactic radiosurgery platforms, and oncology information systems that help hospitals manage treatment workflows.

Revenue is primarily generated when cancer centers and hospitals purchase new equipment or upgrade their installed base, a process that typically involves long sales cycles, extensive clinical validation, and service contracts that can extend over many years. Elekta also earns recurring income from software licenses, maintenance contracts, training, and consumables linked to certain treatment modalities, which together create a mix of one-off project revenue and ongoing service streams.

The company’s business model is influenced by public and private healthcare spending decisions, as radiotherapy equipment is capital intensive and often financed through multi?year investment programs. Elekta competes with other major radiation oncology providers and aims to differentiate through precision treatment technologies, interoperability with hospital IT systems, and a focus on improving patient throughput and care quality, according to company materials updated during its recent earnings cycle Elekta product information as of 02/27/2025.

Main revenue and product drivers for Elekta AB

Linear accelerators, often referred to as linacs, represent one of Elekta’s most important product categories and are central to the company’s revenue base. These large machines deliver high?energy radiation beams to target tumors while sparing surrounding tissue, and they are typically installed in dedicated treatment rooms. Orders for linacs are influenced by hospital expansion projects, replacement of older equipment, and the adoption of advanced treatment techniques such as intensity?modulated or image?guided radiotherapy.

In addition to hardware, Elekta’s treatment planning software and oncology information systems form a key component of its growth strategy. These software platforms support clinicians in designing radiation treatment plans, managing patient data, and coordinating multi?disciplinary care. Because software licenses and upgrades can be sold into the existing installed base of hardware, they provide an avenue for incremental revenue without the need for a full equipment replacement at each site.

Brachytherapy and stereotactic radiosurgery systems add further diversification across disease indications and clinical settings. Brachytherapy involves placing radioactive sources close to or inside the tumor, while radiosurgery platforms are often used for brain and spine lesions that require high precision. The company also benefits from multi?year service contracts that cover maintenance, calibration, and technical support, providing a recurring revenue component which can help smooth fluctuations in capital equipment demand.

Why Elekta AB matters for US investors

Although Elekta AB is headquartered in Sweden and listed on Nasdaq Stockholm, its radiotherapy systems and software are used by cancer centers around the world, including in North America. For US?based investors who follow the global medical technology sector, the company offers exposure to the expanding market for radiation oncology equipment, which is driven by demographic trends and increases in cancer incidence as populations age.

US healthcare providers often play a leading role in adopting advanced radiotherapy techniques and digital oncology workflows. As a result, Elekta’s competitive positioning in key US hospital systems and cancer networks can be an indicator of its technological relevance and potential to capture high?value projects. The company’s performance is also influenced by reimbursement policies, capital spending cycles, and regulatory approvals in the United States, making developments in the US healthcare environment relevant for assessing its long?term demand profile.

From a portfolio perspective, Elekta’s Stockholm listing means the stock is denominated in Swedish krona, so US investors who access it via international brokerage accounts or through funds must consider currency movements alongside company?specific factors. Changes in the SEK–USD exchange rate can influence reported returns in dollars, even when the underlying share price on the Swedish market is stable.

Conclusion

Elekta AB remains a specialized player in the global radiation oncology market, with revenue driven by sales of linear accelerators, brachytherapy systems, and related software and services. Recent quarterly results and company communications suggest continued demand for radiotherapy solutions, but also underline the influence of healthcare investment cycles and competitive dynamics. For US?focused investors, the stock provides international exposure to cancer treatment technologies, with additional layers of complexity from currency movements and regional policy trends. As with any medtech investment, developments in clinical adoption, reimbursement frameworks, and capital spending plans will be important to monitor over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.